Zacks Investment Research
30 Jul 2026, 23:00 UTC · 10w ago
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
Impact · against what's priced in
Castle Biosciences (CSTL) demonstrated strong operational momentum with a significant beat on both earnings and revenue. While the stock has struggled year-to-date, the substantial surprise in quarterly performance suggests an improvement in fundamental execution that may outweigh the prevailing negative price trend.
- CSTL+0.40
No priced-in read yet
- In context
The company reported a quarterly loss of $0.07 per share against a consensus estimate of a $0.44 loss, and revenues of $103.55 million, beating estimates by 18.61%.
Read from the article alone
Search tags
